Radiolabeled peptide probe for tumor imaging

Ya Qiong Yan, Hao Wang, Yuliang Zhao

Research output: Contribution to journalArticlepeer-review


Radionuclide imaging is now the premier imaging method in clinical practice for its high sensitivity and tomographic capability. Current clinically available radio imaging methods mostly use positron-emission tomography (PET) and single-photon emission computed tomography (SPECT) to detect anatomic abnormalities that conventional imaging techniques typically have challenges for visualizing. Contrast agents are indispensable for radionuclide imaging, and the radionuclide is always attached to a suitable vector that achieves targeted delivery. Nowadays, peptides have attracted increasing interest in targeting vectors of contrast agents, mainly due to their high specificity for target receptors at nanomolar concentrations and low toxicity. Radiolabeled peptide probes as kinds of PET/SPECT tracers had become essential tools for clinical radionuclide diagnosis. This review mainly summarizes radiolabeled peptide probes for bioimaging, including fundamental concepts of radiolabeled peptide probe design, some typical peptide analogs radiocontrast agents for PET, SPECT, and the combination imaging.

Original languageEnglish (US)
JournalChinese Chemical Letters
StateAccepted/In press - 2022


  • Bioimaging
  • Peptide
  • Positron-emission tomography (PET)
  • Single-photon emission computed tomography (SPECT)

ASJC Scopus subject areas

  • Chemistry(all)


Dive into the research topics of 'Radiolabeled peptide probe for tumor imaging'. Together they form a unique fingerprint.

Cite this